Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tear film stabilization (pre-corneal) refers to the maintenance and regulation of the thin, multi-layered fluid film that coats the anterior surface of the cornea. This tear film is essential for ocular surface health, optical clarity, and comfort. Its stability depends on a complex interplay of lipids, aqueous components, and mucins, and it is not a single molecular target but a physiological process involving multiple components. Instability is a key factor in dry eye disease. Therapeutic interventions aim to restore or maintain tear film stability by supplementing tear components or addressing underlying causes of instability such as inflammation.
Artificial tears provide lubrication and supplement tear film components. Cyclosporine and lifitegrast reduce inflammation to improve tear production and quality.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tear Film Stabilization (Pre-corneal) (TFS).